Join ABL at Phacilitate Jan. 26-28 – Director of Immunobiology to Discuss the Future of Cancer Immunotherapies
Washington, D.C. – January 20, 2015 – ABL is attending the Phacilitate conference to speak with industry leaders on immunological research and cGMP biologics manufacturing opportunities across all three simultaneous forums. The conference, hosted at the Grand Hyatt in Washington, D.C. January 26-28, 2015, has over 150 speakers in their Cell & Gene Therapy Forum, Immunotherapy Forum, and Stem Cells as Discovery Research Tools Forum.
Stop by ABL’s booth to talk through ABL’s service offerings and potential partnering opportunities. Please also attend the panel discussion “What advancements can we expect in the short and longer term to optimize the specificity and selectivity of the next generation immunotherapeutic agents to deal with the diversity that is the tumor?” featuring leading international immunologists, including ABL’s Director of Immunobiology and Head of Clinical Testing, Dr. Anthony Cristillo. This event with Dr. Cristillo wll take place on January 28 from 10:45-11:20. Discussion points will include:
- What additional functions should the T cells/molecules be equipped with going forward?
- Are they going to require antigen specificity or not?
- Early insight into advancements in the bladder, colon and head & neck cancer fields
About ABL, Inc.
ABL, Inc. is a global biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including the U.S. Government, biopharmaceutical companies and academic entities. Notable contract manufacturing services include process and assay development, cGMP biologics manufacturing of bulk drug substance, cGMP aseptic fill and finish of drug product, and QC analytics in the U.S. and Europe. ABL also maintains U.S. and European immunological and molecular laboratories to support preclinical and GCLP clinical sample processing and testing. ABL is a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally.
For more information visit www.ablinc.com or email us.
